Effects and risks associated with novel psychoactive substances: Mislabeling and sale as bath salts, spice, and research chemicals;Wirkungen und risiken neuartiger psychoaktiver substanzen: Fehldeklaration und verkauf als "badesalze", "spice" und "forschungschemikalien"

Deutsches Arzteblatt International

Volumn 111, Issue 9, 2014, Pages 139-147

  Hohmann, Nicolas ^a   Mikus, Gerd ^a   Czock, David ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Medizinische Klinik (Krehl Klinik)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CATHINONE; PSYCHOTROPIC AGENT; STREET DRUG;

AGITATION; DRUG DEPENDENCE; DRUG INTOXICATION; DRUG LABELING; DRUG MONITORING; DRUG TRAFFIC; DRUG USE; HUMAN; HYPERTENSION; MOOD CHANGE; PERCEPTION; REVIEW; RISK ASSESSMENT; TACHYCARDIA; AKATHISIA, DRUG-INDUCED; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; INTOXICATION; MENTAL DISORDERS; SPICE;

AKATHISIA, DRUG-INDUCED; CARDIOVASCULAR DISEASES; DRUG LABELING; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; RISK ASSESSMENT; SPICES; STREET DRUGS;

EID: 84899521528     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2014.0139     Document Type: Review

References (40)

1. Europäische Beobachtungsstelle für Drogen und Drogensucht: Drogenangebot in Europa. In: Europäischer Drogenbericht 2013: Trends und Entwicklungen. Luxemburg: Amt für Veröffentlichungen der Europäischen Union 2013; 28-9.
2. Nobis: "Legal-High"-Produkte - wirklich illegal? - Oder: Wie ein Aufsatz sich verselbstständigt! NStZ 2012; 422.
3. Fattore L, Fratta W, Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci 2011; 5: 60.
4. Bernhard C, Werse B, Schell-Mack C: Jahresbericht MoSyD. Drogentrends in Frankfurt am Main 2012. Centre for Drug Research 2013.
5. Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V: Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108: 534-44.
6. Musshoff F, Madea B, Kernbach-Wighton G, et al.: Driving under the influence of synthetic cannabinoids ("Spice"): a case series. Int J Legal Med 2014: 128: 59-64.
7. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K: Withdrawal phenomena and dependence syndrome after the consumption of "spice gold". Dtsch Arztebl Int 2009; 106: 464-7.
8. Glennon RA, Yousif M, Naiman N, Kalix P: Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 1987; 26: 547-51. (Pubitemid 17047729)
9. Kelly JP: Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011; 3: 439-53.
10. Karila L, Reynaud M: GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011; 3: 552-9.
11. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J: Mephedrone: use, subjective effects and health risks. Addiction 2011; 106: 1991-6.
12. Wood KE: Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013; 163: 213-6.
13. Spiller HA, Ryan ML, Weston RG, Jansen J: Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clin Toxicol 2011; 49: 499-505.
14. Marinetti LJ, Antonides HM: Analysis of synthetic cathinones commonly found in bath salts in human performance and post-mortem toxicology: method development, drug distribution and Interpretation of Results. J Anal Toxicol 2013; 37: 135-46.
15. Schifano F, Albanese A, Fergus S, et al. and Psychonaut Web Mapping, ReDNet Research Groups: Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011; 214: 593-602.
16. Ross EA, Watson M, Goldberger B: "Bath salts" intoxication. N Engl J Med 2011; 365: 967-8.
17. Freeman TP, Morgan CJ, Vaughn-Jones J, Hussain N, Karimi K, Curran HV: Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 2012; 107: 792-800.
18. Belton P, Sharngoe T, Maguire FM, Polhemus M: Cardiac infection and sepsis in 3 intravenous bath salts drug users. Clin Infect Dis 2013; 56: e102-4.
19. Wood DM, Davies S, Greene SL, et al.: Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010; 48: 924-7.
20. Murphy CM, Dulaney AR, Beuhler MC, Kacinko S: "Bath salts" and "plant food" products: the experience of one regional US poison center. J Med Toxicol 2013; 9: 42-8.
21. Penders TM, Gestring RE, Vilensky DA: Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry 2012; 34: 647-50.
22. Nicholson PJ, Quinn MJ, Dodd JD: Headshop heartache: acute mephedrone 'meow' myocarditis. Heart 2010; 96: 2051-2.
23. Loeffler G, Penn A, Ledden B: "Bath salt"-induced agitated paranoia: a case series. J Stud Alcohol Drugs 2012; 73: 706.
24. Borek HA, Holstege CP: Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 2012; 60: 103-5.
25. Schifano F, Corkery J, Ghodse AH: Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. J Clin Psychopharmacol 2012; 32: 710-4.
26. Centers for Disease Control and Prevention: Acute kidney injury associated with synthetic cannabinoid use-multiple states 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 93-8.
27. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N: 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44: 832-7.
28. Seely KA, Prather PL, James LP, Moran JH: Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011; 11: 36-51.
29. Simolka K, Lindigkeit R, Schiebel HM, Papke U, Ernst L, Beuerle T: Analysis of synthetic cannabinoids in "spice-like" herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 2012; 404: 157-71.
30. Hillebrand J, Olszewski D, Sedefov R: Legal highs on the internet. Subst Use Misuse 2010; 45: 330-40.
31. Griffiths P, Sedefov R, Gallegos A, Lopez D: How globalization and market innovation challenge how we think about and respond to drug use: 'Spice' a case study. Addiction 2010; 105: 951-3.
32. Müller H, Sperling W, Köhrmann M, Huttner HB, Kornhuber J, Maler JM: The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309-10.
33. de Boer D, Bosman IJ, Hidvegi E, et al.: Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. For Sci Int 2001; 121: 47-56.
34. Elliott S: Current awareness of piperazines: pharmacology and toxicology. Drug Test Anal 2011; 3: 430-8.
35. Thompson I, Williams G, Caldwell B, et al.: Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol 2010; 24: 1299-308.
36. Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P: Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol 2008; 46: 802-7.
37. Coppola M, Mondola R: 5-iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicol Lett 2013; 218: 24-9.
38. Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA: Aminoindanes-the next wave of 'legal highs'? Drug Test Anal 2011; 3: 479-82.
39. Corazza O, Schifano F, Farre M, et al.: Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011; 6: 125-9.
40. Thorlacius K, Borna C, Personne M: Bromo-dragon fly - life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case. Lakartidningen 2008; 105: 1199-200.